The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified.
Fund filings (PDF) »
Christopher Lee (Started: May 1, 2016)
Steven Kornfeld (Started: Sep 15, 2015)
Evan McCulloch (Started: Sep 15, 1997)
# Contact ?>
Franklin Templeton Investments, One Franklin Parkway, Building 970, 1st Floor, Rancho Cardova, CA 95670, USA